BioXcel Therapeutics, Inc. (BTAI)

28.74
0.69 2.50
NASDAQ
Prev Close 28.05
Open 28.30
Day Low/High 28.14 / 29.88
52 Wk Low/High 23.07 / 67.74
Volume 278.13K
Exchange NASDAQ
Shares Outstanding 27.97B
Market Cap 757.68M
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

You've Got Volatility 'Covered' With This Strategy

You've Got Volatility 'Covered' With This Strategy

This simple option strategy, which I continue to use with small-cap biotechs, is one of the easiest and cheapest risk mitigation approaches an individual can take.

I See Covered Call Opportunities in These 2 Biotechs

I See Covered Call Opportunities in These 2 Biotechs

I continue to put new money to work in BioXcel Therapeutics and GoHealth.

An All-Terrain Strategy for Portfolio Management

An All-Terrain Strategy for Portfolio Management

The market's mood seems to be changing almost daily; he's an approach for how to trade it regardless of how it's feeling on any particular day.

One Man's Plan for Navigating the Choppy Rising Rate Seas

One Man's Plan for Navigating the Choppy Rising Rate Seas

Putting cash to work on significant market pullbacks such as the one that occurred Thursday is a key element of the strategy.

2 Potential Acquisition Targets as Biotech Deal Activity Picks Up

2 Potential Acquisition Targets as Biotech Deal Activity Picks Up

BioXcel Therapeutics and Avadel Pharmaceuticals would make good additions to the portfolios of larger drug companies.

Biotech M&A Picks Up: Lessons for Investors and Potential Targets

Biotech M&A Picks Up: Lessons for Investors and Potential Targets

The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.

This Is Great Action for Stock Pickers Right Now

This Is Great Action for Stock Pickers Right Now

Stick to themes like biotechnology, SPACs, EV batteries, and others.

2 Small Biotechs That Have Attracted My Attention and My Cash

2 Small Biotechs That Have Attracted My Attention and My Cash

BioXcel Therapeutics and Avadel Pharmaceuticals are new additions to my personal portfolio based on their promising drug prospects.

Stubborn Market Refuses to Budge From Uptrend

Stubborn Market Refuses to Budge From Uptrend

Most notable is how the coronavirus issue is having no negative impact.